达安基因
(002030)
| 流通市值：92.21亿 | | | 总市值：92.21亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 503,506,935.73 | 338,574,032.79 | 169,136,638.98 | 853,024,340.06 |
| 营业收入 | 503,506,935.73 | 338,574,032.79 | 169,136,638.98 | 853,024,340.06 |
| 二、营业总成本 | 720,643,863.72 | 488,712,041.64 | 238,175,840.05 | 1,058,064,537.31 |
| 营业成本 | 339,024,438.37 | 226,711,221.69 | 116,639,813.97 | 532,743,357.51 |
| 税金及附加 | 3,449,721.87 | 2,529,942.09 | 957,379.27 | 9,533,974.98 |
| 销售费用 | 157,727,422.3 | 107,190,777.47 | 45,354,577.5 | 208,135,259.78 |
| 管理费用 | 104,168,144.62 | 67,054,419.39 | 31,562,428.43 | 147,052,511.51 |
| 研发费用 | 145,883,697.34 | 104,696,043.57 | 53,947,875.38 | 225,668,337.11 |
| 财务费用 | -29,609,560.78 | -19,470,362.57 | -10,286,234.5 | -65,068,903.58 |
| 其中:利息费用 | 2,752,671.58 | 2,100,374.22 | 1,220,515.45 | 9,744,538.33 |
| 其中:利息收入 | 37,460,940.92 | 26,033,375.07 | 13,156,077.19 | 69,372,365.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 206,552,477.7 | 85,568,280.89 | 200,727,294.7 | -175,745,759.4 |
| 加:投资收益 | -4,987,597.19 | 4,777,877.08 | -24,752,707.19 | -253,838,060.16 |
| 资产处置收益 | 2,535,897.78 | 476,575.74 | 4,911.43 | 9,096,715.23 |
| 资产减值损失(新) | -7,665,953.46 | -5,828,434.13 | -3,490,664.44 | -75,039,742.89 |
| 信用减值损失(新) | -172,301,387.88 | -171,131,831.27 | -22,202,238.09 | -407,831,786.93 |
| 其他收益 | 27,603,870.23 | 19,908,076.46 | 11,929,429.77 | 40,793,337.41 |
| 四、营业利润 | -165,399,620.81 | -216,367,464.08 | 93,176,825.11 | -1,067,605,493.99 |
| 加:营业外收入 | 2,459,191.88 | 1,534,695.23 | 793,129.91 | 2,584,173.89 |
| 减:营业外支出 | 6,632,875.71 | 4,350,805.79 | 140,725.39 | 6,142,074.3 |
| 五、利润总额 | -169,573,304.64 | -219,183,574.64 | 93,829,229.63 | -1,071,163,394.4 |
| 减:所得税费用 | -18,798,396.95 | -29,058,942.1 | 42,566,394.4 | -132,050,533.38 |
| 六、净利润 | -150,774,907.69 | -190,124,632.54 | 51,262,835.23 | -939,112,861.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -150,774,907.69 | -190,124,632.54 | 51,262,835.23 | -939,112,861.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -141,504,567.19 | -182,160,988.3 | 52,924,282 | -925,169,864.75 |
| 少数股东损益 | -9,270,340.5 | -7,963,644.24 | -1,661,446.77 | -13,942,996.27 |
| 扣除非经常损益后的净利润 | -324,683,164.12 | -264,517,382.29 | -98,960,664.05 | -822,653,095.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | -0.13 | 0.04 | -0.66 |
| (二)稀释每股收益 | -0.1 | -0.13 | 0.04 | -0.66 |
| 八、其他综合收益 | -521,826.97 | -691,778.51 | -38,440.51 | -3,309,277.01 |
| 归属于母公司股东的其他综合收益 | -430,784.58 | -597,420.11 | -22,401.25 | -3,491,876.88 |
| 九、综合收益总额 | -151,296,734.66 | -190,816,411.05 | 51,224,394.72 | -942,422,138.03 |
| 归属于母公司股东的综合收益总额 | -141,935,351.77 | -182,758,408.41 | 52,901,880.75 | -928,661,741.63 |
| 归属于少数股东的综合收益总额 | -9,361,382.89 | -8,058,002.64 | -1,677,486.03 | -13,760,396.4 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-30 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |